Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?
by Kinjel Shah
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
What's in Store for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.38 in the latest trading session, marking a -1.25% move from the prior day.
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
by Zacks Equity Research
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Here Are the Key Takeaways From J&J's Q1 Earnings Report
by Zacks Equity Research
Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Wave Life Sciences Plunges After DMD Study Data Readout
by Zacks Equity Research
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
by Zacks Equity Research
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
by Swarup Gupta
The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.73, moving -0.26% from the previous trading session.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval
by Swarup Gupta
The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $42.74, marking a -0.23% move from the previous day.